LILRA4

LILRA4 Informations sur la molécule

Nom anglais	Leukocyte immunoglobulin-like receptor subfamily A member 4	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Leukocyte immunoglobulin-like receptor subfamily A member 4
Alias de la cible	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 2 Clinical

LILRA4 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
His Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
LI4-H5243	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified)				Ajouter au panier
LI4-H52H5	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag				Ajouter au panier

Quantité totale2

LILRA4Contexte de la molécule

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4Alias de la molécule

LILRA4,CD85g,ILT7,ILT-7

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Daxdilimab	MEDI-7734; VIB-7734; HZN-7734	Phase 2 Clinical	Horizon Therapeutics PLC, Sbi Biotech Co Ltd	Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome	Details